Background Acute exposure to air pollution has been linked to myocardial infarction, but its eff ect on heart failure is uncertain. We did a systematic review and meta-analysis to assess the association between air pollution and acute decompensated heart failure including hospitalisation and heart failure mortality.
Introduction
The adverse eff ects of air pollution on cardiovascular health have been established in a series of major epidemiological and observational studies. [1] [2] [3] [4] WHO estimates that air pollution is responsible for over a million premature deaths worldwide every year. 5 Even brief exposures to air pollution have been associated with increases in cardiovascular mortality, 6, 7 particularly in susceptible populations.
Heart failure is an escalating public health issue that aff ects more than 23 million people worldwide, 8 with an increasing prevalence in elderly people. 9, 10 It has an annual hospitalisation rate of 2% with subsequent 1-year mortality of 30%. 11 Heart failure ranks as the most frequent reason for hospitalisation and rehospitalisation in older people, 12, 13 accounting for 5% of all hospital discharge diagnoses. The triggers of acute cardiac decompensation especially in susceptible individuals are therefore a major public health concern.
Population and individual level exposures to air pollution are associated with acute cardiovascular events such as myocardial infarction. 14, 15 However, the eff ect of air pollution on other cardiovascular conditions, such as acute decompensated heart failure, has been less well described. 16 This issue is important because there are major diff erences in the mechanisms that trigger myocardial infarction compared with acute decompensated heart failure. [17] [18] [19] Several studies of short-term exposure to air pollution have included heart failure hospitalisation and mortality, although these endpoints have not been the primary focus in most analyses. We therefore systematically reviewed the evidence examining the association between air pollution and acute decompensated heart failure, including hospitalisation and heart failure mortality.
Selection of articles and extraction of data
Studies were included if they presented original data for gaseous (carbon monoxide, sulphur dioxide, nitrogen dioxide, ozone) or particulate (PM 2·5 or PM 10 ) air pollutants and reported heart failure hospitalisation or heart failure mortality. We included all studies that reported associations between exposure and outcome up to and including lag (day) 7. There were no language restrictions and we included only peer-reviewed original articles.
Data were extracted independently by two investigators (ASVS and JPL) and confl icts were adjudicated by a third investigator (ALH). We contacted authors for additional data or clarifi cation where needed.
Both case-crossover and time-series studies were included. The case-crossover design compares exposure in a case period when the event occurred with exposure in specifi ed control periods. 20 This design can control for individual characteristics such as age, sex, and comorbidity, as well as secular trends and seasonal patterns using a time-stratifi ed approach, but assumes time-varying risk factors are constant within reference periods. 21 Time-series studies were used to assess the relation between exposure and outcome using regression analysis account ing for confounding factors, such as meteorological param eters, but are less eff ective at controlling for secular trends such as seasonality. 22 The study design, study popu lation, and adjustment undertaken for potential confound ers have been summarised for each study in the appendix.
Data synthesis
Relative risks (RR) were pooled for a standardised increment in pollutant concentration as follows: 10 μg/m³ for PM 2·5 and PM 10 , 10 parts per billion for nitrogen dioxide (NO 2 ), sulphur dioxide (SO 2 ), and ozone (O 3 ), and 1 part per million for carbon monoxide (CO). Many studies used generalised linear models and therefore we assumed a linear relation between exposure and outcome. Standardised risk estimates were calculated for each study using the following formula:
Four studies reported stratifi ed risk estimates by age, 23 location, 24 and temperature 25, 26 rather than overall risk estimates, and the stratifi ed estimates were included in our meta-analysis. Two studies reported results from the same population using both case-crossover and timeseries analysis 27, 28 and estimates from the time-series analyses were included. Three studies [29] [30] [31] subsequently revised their time series analyses and the revised estimates were included. 32, 33 Time-series analyses were mainly based on routine administrative datasets and did not adjust for individual characteristics such as age, sex, or socioeconomic status. For all studies, we pooled adjusted risk estimates controlling for meteorological, temporal, and seasonal parameters (appendix).
Many studies provided multiple estimates for single lags (for example lag 0 or lag 1) and were pooled separately. We only pooled estimates for single lags where more than three estimates were available. The shortest lag was used to assess overall risk estimates. A few studies only provided cumulative lags (for example lag 0-1 or 0-2), and were not suitable for pooling in the single lag analysis, but were used to determine overall risk estimates.
Additional analyses
We did additional analyses stratifying studies by study design (time-series vs case-crossover), geographical location (USA vs non-USA), age (all ages vs ≥65 years of age), and outcome (heart failure hospitalisation vs heart failure mortality). We assumed that the prevalence of air pollution exposure was 100% and therefore calculated population-attributable risks per pollutant using our overall risk estimates and the formula:
Funnel plots were constructed for assessment of publication bias (data not shown) and assessed for asymmetry using Egger's regression test. 34 Asymmetry was then corrected using the trim and fi ll method, with adjusted relative risks and number of studies adjusted presented per pollutant. 35 We used PM 2·5 to illustrate the potential eff ect of reducing air pollution concentration on heart failure hospitalisations in the USA. For each state we obtained the number of heart failure hospitalisations and average cost per hospitalisation (amount charged for the hospital stay excluding professional fees) from the US Healthcare Cost and Utilization Project State Inpatient Database 13 and the Chronic Condition and Data Warehouse (appendix). The median daily PM 2·5 concentration was calculated for each state from the Centers for Disease Control and Prevention's Wide-ranging Online Data for Epidemiologic Research (WONDER) database. In each state, we estimated the population-attributable risks and annual reduction in heart failure hospitalisations per 100 000 people for a reduction in PM 2·5 concentration to 5·8 μg/m³. This concentration represents a target threshold below which the adverse health eff ects of PM 2·5 are uncertain. 36, 37 
Statistical analysis
We anticipated heterogeneity between studies due to diff erent study designs, methods of analysis, diff erent lag exposures, and geographical and population diff erences. We used a random-eff ects model to account for both within and between study heterogeneity. Heterogeneity was examined using the standard I² test. As this test has limited power when applied to a small number of studies, we considered the presence of heterogeneity at 10% level of signifi cance and I² exceeding 30%. The analysis was 
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Results
The abstracts of 1146 articles were assessed and 195 studies underwent in-depth review, with 35 studies fulfi lling the inclusion criteria. Ten studies used a case-crossover 24, 27, 29, 30, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] and one used both study designs 67 incorporating four million events across the world (table 1) .
There was a positive association between heart failure hospitalisation or heart failure mortality, and all gaseous and particulate air pollutants except ozone (fi gure 1). The strongest associations were seen at lag 0, with this eff ect diminishing at longer lag times. Carbon monoxide was the most frequently studied gaseous pollutant, and showed a 3·52% (95% CI 2·52-4·54%) increase in heart failure hospitalisations or mortality per 1 part per million increment across nearly two million events. Both PM 2·5 (2·12%, 95% CI 1·42-2·82) and PM 10 (1·63%, 1·20-2·07) were positively associated with heart failure hospitalisation or mortality with a marked temporal relation and the strongest associations present at lag 0.
We did additional analyses by outcome, study design, age, and geographical location (fi gure 2). There was no change in eff ect direction across all pollutants in these analyses. Publication bias (Egger's test for asymmetry, p<0·05) was noted for all pollutants except ozone (table 2). Adjusting for asymmetry using the trim and fi ll method did not alter the eff ect direction but, as expected, did attenuate the eff ect size. We observed heterogeneity
Number of events
Number of estimates This study therefore appears twice in the additional analysis when stratifi ed by age. For the overall analysis, we have used the estimates provided for all age groups. †Kwon and Peel et al 27, 28, 67 provided separate estimates stratifi ed by study design and therefore appear twice in the additional analysis. For the overall analysis, we have used the estimates provided for the time-series study design. ppm=parts per million. ppb=parts per billion. across all pollutants, which was most evident for nitrogen dioxide and carbon monoxide (I² of 91%) and least evident for PM 2·5 (I² of 53%). Median daily PM 2·5 concentrations varied across states, with the highest population-attributable risks seen in Mississippi, Kentucky, and Tennessee and the lowest in Utah, Wyoming, and North Dakota (appendix). Reducing PM 2·5 concentrations to 5·8 μg/m³ in each state would require a mean reduction in PM 2·5 of 3·9 μg/m³ across the USA. The greatest eff ect on heart failure hospitalisations would be in those states with the highest median daily PM 2·5 concentrations (fi gure 3). We estimate that this reduction would prevent 7978 heart failure hospitalisations and would be associated with savings of around US$307 million per year (appendix).
Discussion
There were robust and clear temporal associations between exposure to air pollutants and heart failure hospitalisations and mortality. The magnitude and direction of our overall estimates persisted despite conservative modelling. All studies except one were done in developed countries where even modest improvements in air quality standards are projected to have major population health benefi ts and substantial health-care cost savings.
The eff ect of air pollution on heart failure hospitalisation and mortality might be underestimated. First, our estimates are based on acute events associated with short-term exposures and do not take into account the adverse eff ects of chronic exposure to air pollution. 3 We
Figure 3: Median daily PM 2·5 concentrations and estimated impact of a reduction in PM 2·5 to a target concentration on heart failure hospitalisation per US state
Heart failure hospitalisation rates were not available for 15 states (appendix); data not shown for Mississippi (median daily PM 2·5 13·4 μg/m³; annual reduction in heart failure hospitalisations 15 per 100 000). US state abbreviations are defi ned in the appendix. , where X indicates prevalence exposure (assumed to be 100% here). §Risk estimates derived from pooled analysis of studies. ¶Risk estimates after adjustment for publication bias using the trim and fi ll method. have not considered long-term studies of air pollution in the current meta-analysis and therefore are unable to quantify any additive temporal eff ects of air pollution. Second, although our meta-analysis estimates the eff ect of short-term increases in air pollution on the population, this eff ect is likely to be greater in patients with pre-existing heart failure. Unfortunately, we were unable to stratify our analysis on the presence, severity, or phenotype of pre-existing heart failure, since these data were not available. Third, regional monitoring sites are likely to underestimate personal exposure in individuals living near major roadways. This may be an important consideration in estimating individual risk given that traffi c-related air pollutants are thought to be the primary mediators of the cardiovascular eff ects of air pollution. 19 A recent assessment of the global burden of disease ranked PM 2·5 air pollution as one of the leading causes of death and disability worldwide. 37 The American Thoracic Society recently advocated stricter standards for PM₂.₅ recommending a 10 μg/m³ reduction in daily maximum concentrations to 25 μg/m³. 68 Recent studies indicate the persistence of adverse health eff ects at concentrations below those recommended by WHO. 69 In our impact analysis, we estimate that reducing median daily PM₂.₅ concentrations by a mean of 3·9 μg/m³ would prevent roughly 8000 heart failure hospitalisations in the USA, with an associated saving of nearly a third of a billion dollars per annum. Smaller reductions in PM 2·5 would prevent fewer hospitalisations, but could still confer signifi cant public health benefi ts.
Urban cities in developing countries are likely to have PM 2·5 concentrations up to 10-fold higher than the US National Ambient Air Quality Standards. 70, 71 So-called megacities, with populations well above 10 million people such as New Delhi in India and Beijing in China, have daily PM 2·5 concentrations of 100-300 μg/m³ compared with a median PM 2·5 concentration of 15 μg/m³ in the cities included in our meta-analysis. 70, 72 However, assessment of the eff ect of air pollution in developing countries is diffi cult because of a lack of cohesive air quality policies in combination with poor environmental monitoring and a paucity of disease surveillance data. 73 The lack of data from developing countries is con cerning because these regions are likely to be aff ected most and have the greatest potential to improve health. The problem is highlighted in our meta-analysis where only one of the 35 studies was done in a developing country. 53 In areas with high levels of air pollution there are likely to be more frequent and more marked changes in air pollution exposure on a daily basis. 72 Whether actual or relative increases in exposure would determine outcomes in these regions is uncertain.
In our additional analysis stratifying studies by location, we found risk estimates were almost twice as high in countries outside the USA where ambient concentrations are generally higher. As such, caution is necessary when extrapolating overall risk estimates from our meta-analysis to regions with higher air pollution concentrations.
Most hospitalisations in patients with heart failure are due to acute decompensated heart failure and dysrhythmias, 74 with fewer patients hospitalised because of coexisting coronary heart disease and pulmonary disease. 16 The biological mechanisms precipitating acute decompensation in patients with heart failure are likely to diff er substantially from those involved in triggering acute myocardial infarction. 19 Acute decompensated heart failure can be caused by increasing demand on the heart, such as increased heart rate, blood pressure, and fi lling pressures, or further impairment of cardiac performance, such as reduced contractility and increased myocardial injury. Exposure to particulate matter air pollution has been associated with increased systemic blood pressure and vasoconstriction. [75] [76] [77] Both pulmonary and right ventricular diastolic fi lling pressures are increased by exposure to ambient particulate matter, suggesting a pulmonary vasoconstrictor eff ect of air pollution. 78 Together with arrhythmias, 79 these eff ects of air pollution will markedly increase the demands on the failing heart and thereby potentially precipitate acute decompensation. In addition to loss of contractile capacity through myocardial infarction, 80 inhalation of particulate matter is associated with adverse ventricular remodelling and a worsening of myocardial fi brosis. 81 These factors could have synergistic detrimental eff ects on cardiac function.
Although particulate matter is considered to be responsible for most adverse cardiovascular outcomes, 82 we cannot exclude an eff ect of non-particulate air pollutants either in isolation or combination. We noted an adverse relation between exposure to all gaseous pollutants except for ozone and heart failure outcomes. The acute eff ects of carbon monoxide exposure on cardiac function are well known, 83 but most of these studies have assessed the eff ects of exposure to more than 1000 parts per million of carbon monoxide as a model of cigarette smoking. 84, 85 Ambient carbon monoxide or nitrogen dioxide con centrations might simply refl ect exposure to road traffi c or combustion derived particles. Chamber studies also show that exposure to gaseous pollutants alone at high ambient concentrations does not cause acute cardiovascular dysfunction. 86, 87 Several limitations of our study should be considered. First, we found signifi cant heterogeneity across all pollutants, which could indicate diff erences in population demographics, sample size, patient characteristics, and exposure misclassifi cation due to variation in the accuracy of regional air pollution monitoring. However, pooled risk estimates showed consistency across all pollutants and the eff ect direction was not changed in our additional analyses. Second, we report estimates for single pollutants, which do not take into consideration potential additive eff ects of multiple pollutants or adjustments for collinearity. 88 Third, meta-analysis of observational studies has limitations with inherent biases. We noticed signifi cant publication bias across all pollutants, except ozone. However, after adjustment for asymmetry, the overall eff ect direction remained unchanged. Fourth, most studies pooled in our meta-analysis used data from routine administrative sources. There was limited validation of outcomes, with coding error and misclassification potentially giving rise to non-diff erential bias. However, nine of the 35 studies in our meta-analysis, encompassing almost 2 million events, used Medicare's hospital claims database. Coding for heart failure has been validated by case note review and found to have 84% agreement with the principal diagnosis. 89 Finally, we did not have access to primary data and were unable to establish whether multiple hospitalisations might have occurred in the same patient. This point is important, since patients with recurrent hospitalisations could be more susceptible to the eff ects of air pollution.
Acute decompensated heart failure is a common, costly, and often fatal condition. Change in gaseous and particulate air pollutant concentrations have a marked and close temporal association with adverse outcomes in heart failure. More high-quality studies are urgently needed to establish the eff ect of air pollution on heart failure outcomes in middle-income and low-income countries. Although the causality and biological mechanisms need further exploration, air pollution is a pervasive public health issue with major cardiovascular and healthcare economic consequences presenting a key target for national and international intervention.
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